What is the target of Cabozantinib?

Cabozantinib (Cabozantinib) is a multi-target tyrosine kinase inhibitor. Its targets mainly include the following receptor kinases:

1.Vascular Endothelial Growth Factor Receptor (Vascular Endothelial Growth Factor Receptor, VEGFR): VEGFR is a key regulator of tumor angiogenesis. Inhibiting its activity can reduce the blood supply of tumors, thereby inhibiting tumor growth and spread.

2.Hepatocyte Growth Factor Receptor (Hepatocyte Growth Factor Receptor, MET): METReceptor kinase is involved in regulating cell proliferation, migration and invasion, and its abnormal activation is closely related to the occurrence and development of tumors.

3.Platelet-Derived Growth Factor Receptor, PDGFR): PDGFR is an important growth factor receptor that promotes tumor cell proliferation and angiogenesis.

By simultaneously inhibiting the activity of these receptor kinases, cabozantinib can interfere with the growth, angiogenesis and metastasis of tumor cells, thereby exerting anti-tumor effects. This strategy of multi-target inhibition can provide more effective therapeutic effects than single-target inhibition in some cases, especially for patients with tumors that are insensitive or resistant to other treatments.

Cabozantinib is not currently on the market in China, and therefore is not included in medical insurance. Therefore, patients cannot purchase it domestically and need to purchase it through overseas channels. There are original and generic drugs of cabozantinib abroad. The original drugs are mainly Japanese original drugs, Turkish original drugs and European version of original drugs. Foreign generic drugs are mainly Laos generic drugs and Bangladeshi generic drugs, with prices ranging from 1,300 to 2,700 yuan, and the ingredients of original drugs and generic drugs are basically the same.